NDAOPHTHALMICSOLUTION/DROPS
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 45m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAREMYD is a fixed-combination ophthalmic solution containing hydroxyamphetamine hydrobromide and tropicamide, used for mydriasis (pupil dilation) during diagnostic eye examinations. It combines a sympathomimetic amine with an anticholinergic agent to achieve rapid and sustained pupil dilation for ophthalmologic procedures.
LOE Approaching
This long-established diagnostic agent is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a consolidating specialty ophthalmology franchise with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAREMYD offers limited career growth as a mature diagnostic agent with zero linked job openings and approaching LOE; roles focus on defensive commercial strategy and managed markets. Career advancement typically requires transition to higher-growth franchises or early-stage products within the organization.
Brand ManagerField Sales Representative
Worked on PAREMYD at Epic Pharma Llc? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.